Cancer immunosurveillance and immunoediting by natural killer cells

Cancer Journal (United States)

Volumn 19, Issue 6, 2013, Pages 483-489

  Gross, Emilie ^a   Sunwoo, John B ^b   Bui, Jack D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

Cancer Immunosurveillance; Cancer Incidence; Immunoediting; Nk (Natural Killer) Cells; Tumor Immunogenicity

Indexed keywords

GAMMA INTERFERON; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PROTEIN P53; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER IMMUNOEDITING; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL AGING; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; EXOCYTOSIS; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SARCOMA CELL; SENESCENCE; TUMOR ESCAPE; TUMOR GROWTH;

ANIMALS; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; MICE; NEOPLASMS;

EID: 84889056274     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000005     Document Type: Review

References (91)

1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1-27.
2. Ehrlich P. Ueber des jetzigen Stand der Karzinomforschung. Ned. Tijdschr Geneeskd. 1909;5:273-290.
3. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.
4. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715-727.
5. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
6. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes Curr Opin Immunol. 2007;19:203-208.
7. Bui JD, Uppaluri R, Hsieh CS, et al. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006;66:7301-7309.
8. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
9. DuPage M, Mazumdar C, Schmidt LM, et al. Expression of tumourspecific antigens underlies cancer immunoediting. Nature. 2012;482: 405-409.
10. Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cellYdependent mechanism of cancer immunoediting. Nature. 2012;482:400-404.
11. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-1111.
12. Vesely MD, Kershaw MHD, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-271.
13. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 2005;437:141-146.
14. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors. 2010;36:274-288.
15. Bernardini G, Gismondi A, Santoni A. Chemokines and NK cells: regulators of development, trafficking and functions. Immunol Lett. 2012;145:39-46.
16. Morris MA, Ley K. Trafficking of natural killer cells. Curr Mol Med. 2004;4:431-438.
17. Smyth MJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol. 2005;42:501-510.
18. Long EO, Kim HS, Liu D, et al. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227-258.
19. Storkus WJ, Alexander J, Payne JA, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A. 1989;86:2361-2364.
20. Grundemann C, Bauer M, Schweier O, et al. Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol. 2006;176:1311-1315.
21. Haliotis T, Ball JK, Dexter D, et al. Spontaneous and induced primary oncogenesis in natural killer (NK)-cellYdeficient beige mutant mice. Int J Cancer. 1985;35:505-513.
22. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000;191:661-668.
23. Kreisel D, Gelman AE, Higashikubo R, et al. Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res. 2012;72:4311-4317.
24. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13:459-463.
25. Street SE, Zerafa N, Iezzi M, et al. Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res. 2007;67:5454-5460.
26. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445:656-660.
27. O'Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med. 2012;209:1869-1882.
28. Smyth MJ, Swann J, Cretney E, et al. NKG2D function protects the host from tumor initiation. J Exp Med. 2005;202:583-588.
29. Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28:571-580.
30. Elboim M, Gazit R, Gur C, et al. Tumor immunoediting by NKp46. J Immunol. 2010;184:5637-5644.
31. van den Broek ME, Kagi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184:1781-1790.
32. Smyth MJ, Thia KY, Street SE, et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192:755-760.
33. Street SE, Hayakawa Y, Zhan Y, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med. 2004;199:879-884.
34. Street SE, Trapani JA, MacGregor D, et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med. 2002;196:129-134.
35. Zerafa N, Westwood JA, Cretney E, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol. 2005;175: 5586-5590.
36. Cohen M, Elkabets M, Perlmutter M, et al. Sialylation of 3-methylcholanthreneYinduced fibrosarcoma determines antitumor immune responses during immunoediting. J Immunol. 2010;185: 5869-5878.
37. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gammaYdependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998;95:7556-7561.
38. O'Sullivan T, Dunn GP, Lacoursiere DY, et al. Cancer immunoediting of the NK group 2D ligand H60a. J Immunol. 2011;187:3538-3545.
39. Herberman RB, Nunn ME, Holden HT, et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975;16:230-239.
40. Kiessling R, Klein E, Wigzell H. ''Natural'' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5:112-117.
41. Gorelik E, Rosen B, Copeland D, et al. Evaluation of role of natural killer cells in radiation-induced leukemogenesis in mice. J Natl Cancer Inst. 1984;72:1397-1403.
42. Roder J, Duwe A The beige mutation in the mouse selectively impairs natural killer cell function. Nature. 1979;278:451-453.
43. Roder JC. The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol. 1979;123:2168-2173.
44. Roder JC, Lohmann-Matthes ML, Domzig W, et al. The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol. 1979;123:2174-2181.
45. Carlson GA, Marshall ST, Truesdale AT. Adaptive immune defects and delayed rejection of allogeneic tumor cells in beige mice. Cell Immunol. 1984;87:348-356.
46. Gallin JI, Bujak JS, Patten E, et al. Granulocyte function in the Chediak-Higashi syndrome of mice. Blood. 1974;43:201-206.
47. Jones-Carson J, Vazquez-Torres A, Balish E. Defective killing of Candida albicans hyphae by neutrophils from beige mice. J Infect Dis. 1995;171:1664-1667.
48. Saxena RK, Saxena QB, Adler WH. Defective T-cell response in beige mutant mice. Nature. 1982;295:240-241.
49. Takeuchi K, Wood H, Swank RT. Lysosomal elastase and cathepsin G in beige mice. Neutrophils of beige (Chediak-Higashi) mice selectively lack lysosomal elastase and cathepsin G. J Exp Med. 1986;163:665-677.
50. Nishikado H, Mukai K, Kawano Y, et al. NK cellYdepleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J Immunol. 2011;186:5766-5771.
51. Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature. 2011; 479:547-551.
52. Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134:657-667.
53. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol. 2005;6:928-937.
54. Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6:722-729.
55. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903-907.
56. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
57. Zhou G, Lu Z, McCadden JD, et al. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med. 2004;200:1581-1592.
58. Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol. 2009;86:1105-1109.
59. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: ''N1'' versus ''N2'' TAN. Cancer Cell. 2009;16:183-194.
60. Farnault L, Sanchez C, Baier C, et al. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol. 2012;2012:421702.
61. Yokose N, Ogata K, Ito T, et al. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. Leuk Res. 1994;18:777-782.
62. Chitadze G, Bhat J, Lettau M, et al. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol. 2013;78:120-129.
63. Hilpert J, Grosse-Hovest L, Grunebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012; 189:1360-1371.
64. Koch J, Steinle A, Watzl C, et al. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013;34:182-191.
65. Li T, Yang Y, Hua X, et al. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett. 2012;318:154-161.
66. Pietra G, Manzini C, Rivara S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012;72:1407-1415.
67. Song H, Kim J, Cosman D, et al. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol. 2006;239:22-30.
68. Wu JD, Atteridge CL, Wang X, et al. Obstructing shedding of the immunostimulatory MHC class I chainYrelated gene B prevents tumor formation. Clin Cancer Res. 2009;15:632-640.
69. Classen CF, Falk CS, Friesen C, et al. Natural killer resistance of a drugresistant leukemia cell line, mediated by up-regulation of HLA class I expression. Haematologica. 2003;88:509-521.
70. Lin A, Yan WH, Xu HH, et al. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol. 2007;18:1804-1809.
71. Maki G, Hayes GM, Naji A, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008;22:998-1006.
72. Placke T, O rgel M, Schaller M, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012; 72:440-448.
73. Carayol G, Giron-Michel J, Azzarone B, et al. Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients. Oncogene. 2000;19:2758-2766.
74. Jin J, Fu B, Mei X, et al. CD11b(j)CD27(j) NK cells are associated with the progression of lung carcinoma. PLoS One. 2013;8:e61024.
75. Terme M, Ullrich E, Aymeric L, et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 2012; 72:2757-2767.
76. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006;176:1517-1524.
77. Kim S, Iizuka K, Kang HS, et al. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol. 2002;3:523-528.
78. Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239-252.
79. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010-4017.
80. Shimasaki N, Campana D. Natural killer cell reprogramming with chimeric immune receptors. Methods Mol Biol. 2013;969:203-220.
81. Chang YH, Connolly J, Shimasaki N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73:1777-1786.
82. Kohrt HE, Houot R, Marabelle A, et al. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4:511-527.
83. Benson DM Jr, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012;120:4324-4333.
84. Vey N, Bourhis JH, Boissel N, et al. A phase 1 trial of the antiinhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120:4317-4323.
85. Imai K, Matsuyama S, Miyake S, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year followup study of a general population. Lancet. 2000;356:1795-1799.
86. Hayashi T, Imai K, Morishita Y, et al. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Ceancer Res. 2006;66: 563-570.
87. Balsamo M, VermiW, Parodi M, et al. Melanoma cells become resistant to NK-cellYmediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor. Eur J Immunol. 2012; 42:1833-1842.
88. Tallerico R, Todaro M, Di Franco S, et al. Human NK cells selective targeting of colon cancer-initiating cells: A role for natural cytotoxicity receptors and MHC class I molecules. J Immunol. 2013; 190:2381-2390.
89. Tseng HC, Arasteh A, Paranjpe A, et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One. 2010;5:e11590.
90. Lakshmikanth T, Burke S, Ali TH, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009;119:1251-1263.
91. McGilvray RW, Eagle RA, Watson NF, et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009;15:6993-7002.